Monitoring for disease progression and treatment response in persons with CHRONIC HEPATITIS B prior to, during and post-treatment. It is recommended that the following be monitored at least annually:

• - ALT level (and AST for APRI), HBsAg, HBeAg, and HBV DNA levels

(where HBV DNA testing is available)

• - Non-invasive tests (APRI score or FibroScan) to assess for the presence

of cirrhosis, in those without cirrhosis at baseline;

• - If on treatment, adherence should be monitored regularly and at each

visit